• Shon Meek and Robert C Smallridge.
• Division of Endocrinology, Mayo Clinic College of Medicine, Jacksonville, Florida 32224-1865, USA.
• Endocr Pract. 2006 Sep 1; 12 (5): 529-34.

ObjectiveTo determine whether treatment of subclinical hypothyroidism with levothyroxine would improve homocysteine metabolism.MethodsTwenty-four patients with subclinical hypothyroidism who had thyrotropin (thyroid-stimulating hormone or TSH) levels between 5 and 10 microIU/mL and normal free thyroxine concentrations were recruited from a primary care clinic and were randomized to receive levothyroxine (N = 12) or placebo (N = 12) for a period of 6 months in a double-blind, placebo-controlled study. Homocysteine was measured during fasting and after methionine challenge at the beginning and the end of the study in all patients treated with levothyroxine or placebo.ResultsThe 12 patients treated with levothyroxine had normal TSH levels at the end of the study, with a median value of 1.8 microIU/mL. The 12 patients receiving placebo had a median TSH of 6.0 microIU/mL after the 6-month study period. The ratio of fasting homocysteine at 6 months in comparison with baseline was 1.16 (95% confidence interval, 0.90 to 1.63) for the levothyroxine-treated group and 1.00 (0.88 to 1.29) for the placebo group (P = 0.95). The ratio of post-methionine homocysteine at 6 months in comparison with baseline was 1.00 (95% confidence interval, 0.92 to 1.35) for the levothyroxine-treated group and 0.89 (0.68 to 1.05) for the placebo group (P = 0.081).ConclusionIn this study, levothyroxine treatment of patients with subclinical hypothyroidism did not alter homocysteine levels in the fasting or post-methionine states.

32 keywords...

hide…